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ABSTRACT
We have previously shown that decreased expression of CCAAT/Enhancer binding 
protein β (C/EBPβ) inhibits the growth of glioblastoma cells and diminishes their 
transformation capacity and migration. In agreement with this, we showed that C/
EBPβ depletion decreases the mRNA levels of different genes involved in metastasis 
and invasion. Among these, we found S100 calcium binding protein A4 (S100A4) to be 
almost undetectable in glioblastoma cells deficient in C/EBPβ. Here, we have evaluated 
the possible role of S100A4 in the observed effects of C/EBPβ in glioblastoma cells 
and the mechanism through which S100A4 levels are controlled by C/EBPβ. Our 
results show that C/EBPβ suppression significantly reduced the levels of S100A4 in 
murine GL261 and human T98G glioblastoma cells. By employing an S100A4-promoter 
reporter, we observed a significant induction in the transcriptional activation of 
the S100A4 gene by C/EBPβ. Furthermore, overexpression of S100A4 in C/EBPβ-
depleted glioblastoma cells reverses the enhanced migration and motility induced by 
this transcription factor. Our data also point to a role of S100A4 in glioblastoma cell 
invasion and suggest that the C/EBPβ gene controls the invasive potential of GL261 
and T98G cells through direct regulation of S100A4. Finally, this study indicates a 
role of C/EBPβ on the maintenance of the stem cell population present in GL261 
glioblastoma cells.
INTRODUCTION
Glioblastomas (GBM) constitute approximately 
50% of gliomas as well as 20% of intracranial tumors. 
These tumors are characterized by uncontrolled cell 
proliferation, necrosis focus, high angiogenic activity, 
apoptosis resistance and diffuse invasion of neoplastic cells 
into the surrounding tissue, making surgical interventions 
rather ineffective [1]. GBMs represent the most malignant 
type of astrocytomas and, despite advances in treatment, 
they remain refractory to conventional therapies and 
the medium survival of patients is only one year after 
diagnosis [2]. This poor prognosis is probably due, at 
least in part, to the infiltrative nature of these tumors and 
the presence of cellular populations with ability to escape 
therapies and drive tumor recurrence and progression. In 
some cases, these resistant cells exhibit stem properties 
(Glioblastoma Stem cells (GSC) [3].
CCAAT/Enhancer Binding Protein β (C/EBPβ), is a 
member of a family of transcription factors consisting of 
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six structurally related basic leucine-zipper DNA-binding 
protein [4]. C/EBPβ has important roles in numerous 
tissues regulating cellular proliferation and differentiation, 
metabolism, adipogenesis, inflammation, transformation 
and tumorigenesis [5, 6]. This protein is expressed in 
the central nervous system where it plays different roles 
[7, 8]. Our group has shown that C/EBPβ is an important 
factor for neuronal differentiation [9] and regulates the 
expression of several genes involved in inflammatory 
processes and brain injury [10]. Besides, mice lacking 
C/EBPβ show a reduced inflammatory response after an 
excitotoxic insult and are less susceptible to neuronal cell 
loss [11].
The effects of C/EBPβ in tumor development is 
controversial; some evidence suggests that C/EBPβ acts 
as potent promoter of tumorigenesis while others indicate 
that it can have antiproliferative effects. For instance, 
ectopic expression of C/EBPβ in primary fibroblast 
causes cell cycle arrest and is required for RasV12-induced 
senescence [12]. By contrast, it has been observed that 
C/EBPβ is abundant in colorectal tumors [13] and ovarian 
cancer [14] and its expression is associated with tumor 
progression. Recently, some data show that C/EBPβ is 
associated with tumor progression in prostate cancer cells 
and regulates the expression of metastatic genes in these 
tumors [15, 16]. Regarding brain tumors, Homma et al. 
(2006) has shown that expression of C/EBPβ is increased 
in high grade gliomas compared with less aggressive 
gliomas, and patients where the expression of C/EBPβ is 
lower have a longer survival [17]. In this regard, we have 
demonstrated that C/EBPβ plays an important role in the 
regulation of proliferation, migration and invasiveness of 
glioblastoma cells [18]. Furthermore, our results showed 
that a decrease in C/EBPβ expression is associated with 
reduced mRNA levels of different genes involved in 
invasiveness and metastasis, including S100A4 [18].
S100A4, also known as mts1, is a member of the 
S100 family of Ca2+-binding proteins and is thought to 
be directly involved in tumor invasion and metastasis via 
interactions with specific protein targets [19] in a variety 
of tumors, such as breast cancer [20, 21], gastric cancer 
[22], pancreatic cancer [23], colorectal cancer [24], non-
small cell lung cancer [25], and prostate cancer [26]. 
Recent data show that expression of S100A4 in tumors 
of the central nervous system is related to the degree of 
malignancy of the tumor, with a higher expression of 
S100A4 in high-grade gliomas compared to low-grade 
gliomas [27–29].
All these data together prompted us to analyze 
whether C/EBPβ is a direct regulator of S100A4 
expression and if this protein could mediate the observed 
effects of C/EBPβ on migration and invasiveness of 
glioblastoma cells. Also, we have studied the effects of C/
EBPβ depletion on the neurosphere formation of mouse 
glioblastoma GL261cells.
Collectively, these studies show that C/EBPβ 
increases S100A4 levels by directly activating S100A4 
promoter expression in glioblastoma cells and provide 
evidence that S100A4 may contribute to the C/EBPβ-
induced invasiveness. Also, we demonstrate that S100A4 
promotes migration and invasiveness of glioblastoma 
cells. Finally, our results indicate that C/EBPβ depletion 
resulted in an inhibition of proliferation and self-renewal 
of these cells, which is accompanied by a decreased in the 
S100A4 protein levels.
RESULTS
Regulation of S100A4 gene expression by 
C/EBPβ transcription factor
In a previous work [18] we screened two arrays of 
cell cycle and cancer-related genes in order to analyze the 
mechanism involved in the tumorigenic effect of C/EBPβ 
in glioblastoma cells. We identified a number of genes 
involved in different processes, such as cell cycle regulation, 
DNA damage response, adhesion, invasion, and metastasis 
to be differentially expressed in those cells deficient in C/
EBPβ. Among these genes, S100A4 showed extremely 
low levels of expression in the I4 cells. Here we have 
deeply analyzed the regulation of this gene by C/EBPβ. 
Figure 1A shows that the levels of S100A4 mRNA, as 
measured by RT-PCR were significantly decreased (16- 
and 15-fold) in those cells deficient in C/EBPβ (pools I4 
and I5, respectively) compared to controls (pool C1). In 
addition to this reduction in the mRNA levels of S100A4, 
S100A4 protein levels were almost undetectable in these 
cells (Figure 1B). These data are consistent with the PCR 
arrays data suggesting a possible link between C/EBPβ 
and S100A4 during the progression of the tumorigenic 
capacity of glioblastoma cells. We next tested whether other 
members of the S100 family, also involved in tumorigenic 
processes, were also regulated by C/EBPβ. As can be seen 
in Figure 1C, the expression of S100A6, A100A8, and 
S100A10 was also down-regulated in those glioblastoma 
cells deficient in C/EBPβ (pool I4).
C/EBPβ is a direct transcriptional regulator 
of S100A4
To further analyze the role of C/EBPβ in regulating 
S100A4 gene expression, we studied whether C/EBPβ 
regulates S100A4 promoter activity. First, we performed 
an in silico analysis to search for putative C/EBPβ 
binding sites in the S100A4 promoter using TFSEARCH 
and MatInspector programs. We identified a consensus 
binding site for this transcription factor at the position 
–606/–591 (cut-off value: 0.95) suggesting that C/EBPβ 
may directly regulate S100A4 expression. We also 
found a putative binding region for the transcription 
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factor AP1 at the –680/–670 position (cut-off value: 
0.84) (Figure 2A). It has been described that there are some 
interactions between C/EBPβ and AP1 in the regulation 
of gene expression. C/EBPβ can bind to AP1 binding 
elements as homodimers and activate the transcription of 
the target gene, whereas its heterodimerization with Fos or 
Jun leads to an alteration of the DNA binding specificity of 
C/EBPβ to C/EBPβ DNA binding sites [30]
To provide direct evidence that C/EBPβ is 
recruited to the endogenous S100A4 promoter during 
transcription in vivo, we performed standard chromatin 
immunoprecipitation (ChIP) assays, which allow the 
detection of proteins bound to specific regions of DNA 
in vivo. For these assays we used GL261 cells and a 
specific antibody against C/EBPβ to precipitate the 
complex formed by DNA and this transcription factor. 
ChIP analysis with C/EBPβ antibody showed binding 
of this transcription factor to the S100A4 promoter at 
the C/EBPβ and AP1 consensus regions (Figure 2B). As 
a control of specificity of the assay, binding of C/EBPβ 
to the housekeeping β-actin locus was not detected. These 
data indicate that C/EBPβ can interact with two regions of 
the S100A4 promoter.
We next performed transient transfection 
experiments to determine whether C/EBPβ regulates 
the activity of the S100A4 gene by cotransfecting the 
S100A4 promoter-luciferase construct together with the 
pcDNA3/C/EBPβ overexpression construct in GL261 cells 
(Figure 2C). GL261 cells cotransfected with pcDNA3/ 
C/EBPβ plasmid displayed a significant increase in the 
promoter activity of S100A4. Deletion of both C/EBPβ 
and AP1 binding sites resulted in a significantly reduced 
C/EBPβ-induced activity. Subsequently, to assess the 
functional role of the C/EBPβ and AP1 binding sites in 
S100A4 promoter regulation, we performed site-specific 
mutagenesis within these binding regions. We transfected 
the mutated luciferase reporters into GL261 cells and 
compared their activity with that of wild-type S100A4 
promoter. As shown in Figure 2D, disruption of C/EBPβ or 
both C/EBPβ and AP1 binding sites significantly attenuated 
Figure1: Effect of C/EBPβ on S100A4 expression in glioblastoma murine GL261 cell line. (A) Quantification of S100A4 
mRNA levels in GL261 control cell line (C1) and C/EBPβ-depleted (I4, I5) cells by quantitative real time-PCR. As indicated in Methods, 
we used Taqman probes specifics to S100A4 and β-Actin mouse. The graphic shown the means of values 2−∆∆Ct of S100A4/β-actin ± SD. 
***p < 0.001. (B) Representative Western blot showing expression of C/EBPβ and S100A4 in C1, I4 and I5 cell lines. (C) Quantification 
of S100A6, S100A8 and S100A10 mRNA levels in GL261 control cell line (C1) and C/EBPβ-depleted (I4) cells by quantitative real 
time-PCR. As indicated in Methods, we used Fast SYBR Green and primers specifics to S100A6, S100A8, S100A10 and mouse β-Actin. 
The graphic shown the means of values 2−∆∆Ct ± SD. ***p < 0.001.
Oncotarget4372www.impactjournals.com/oncotarget
Figure 2: C/EBPβ actives S100A4 promoter. (A) Schematic diagram of S100A4 promoter showing the localization of C/EBPβ and 
AP1 binding sites. (B) Representative image and quantification of ChIP analysis of C/EBPβ binding to the endogenous S100A4 promoter 
in GL261 cells. DNA before immunoprecipitation was used as positive control (Input) and a region in the actin gene was used as a negative 
control. Data are expressed relative to the input values and represent the mean ± SD determined in three independent experiments. (C) and 
(D) Transient transfection experiments. The entire promoter fragment (pS100A4/1248), a 5’-deletion construct (pS100A4/298), and two 
constructs containing the mutated C/EBPβ (pS100A4/Mut-C/EBPβ) and the mutated C/EBPβ and AP1 binding sites (pS100A4//Mut-  
C/EBPβ-AP1) were created as indicated in Methods. Data are expressed relative to the basal values and represent the mean ± SD luciferase 
activity determined in triplicate in at least three independent experiments. ***p < 0.001.
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S100A4 promoter activity although this reduction was less 
evident than that observed with the deletion construct.
S100A4 overexpression in C/EBPβ-depleted cell 
line reversed invasion and motility induced by 
C/EBPβ
Glioblastoma cells are characterized for their 
capacity to invade normal surrounding tissue. S100A4 
is a well-known inductor of tumor cell motility and 
metastasis in different cancer cells [31], although its role 
in the invasiveness capacity of glioblastoma cells is not 
yet known. Previous data from our laboratory, using the 
“scratch-wound” assay showed that GL261 glioblastoma 
cells depleted of C/EBPβ presented a restricted cell 
motility [18]. Here we have analyzed the effect of S100A4 
overexpression (Figure 3A) in invasion (transwell assay) 
and motility (scratch assay) of control and C/EBPβ-
depleted GL261glioblastoma cells. As shown in Figure 3B, 
overexpression of S100A4 caused a clear increased in the 
invasion capacity of C1, I4 and I5, being more marked in 
the C/EBPβ-depleted cells. The I4 and I5 cells transfected 
with the pIRES2-DsRed-Express vector containing S100A4 
cDNA showed an increase in their invasion capacity to 
levels similar to those found in the non-depleted cells 
(Figure 3B). Regarding cell motility, our results clearly 
Figure 3: Effect of C/EBPβ and S100A4 on GL261 cells invasion capacity. (A) Representative Western blots showing S100A4 
levels in all the cell lines used for the invasion analysis. (B) The invasion capacity of C1, I4 and I5 cells transfected with the S100A4 
expressing vector pIRES2-DsRed-Express or the corresponding control vector were determined on transwell chambers coated with 
Collagen Type IV as described in Methods. Representative images and quantifications are presented. Values are the means ± S.D. of three 
different experiments. Scale bar 50 μm. **p < 0.01; *p < 0.05.
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show that the overexpression of S100A4 increased motility 
in all GL261 cells, C1, I4 and I5 (Figure 4A and 4B). These 
results are in accordance with the invasion results described 
above and suggest that S100A4 gene controls the motility 
of glioblastoma cells and that therefore could mediate the 
effects of C/EBPβ on motility and invasion.
Next, we determined the effect of C/EBPβ depletion 
and S100A4 overexpression (Figure 5A and 5B) on 
invasion and motility in the human glioblastoma cell line 
T98G. Similar to the result observed in GL261 cells, C/
EBPβ depletion in T98G cells caused a marked decrease 
in S100A4 protein content (Figure 5A), invasion capacity 
(Figure 5C and 5D) and cell motility (Figure 6). The 
overexpression of S100A4 in T98G cells, as in GL261 
cells, increased invasion capacity (Figure 5C) and motility 
(Figure 6A and 6B) in both non C/EBPβ-depleted (TC) 
and C/EBPβ-depleted (TI) cells.
Since it has been shown [32, 33] that S100A4 
regulates the expression of invasion- and migration-
associated genes, such as metalloproteases (MMPs), we 
next analyzed the mRNA levels of MMP2, which is known 
to be regulated by S100A4 in esophageal squamous cell 
carcinoma [34]. Indeed, we found a significant decrease 
in MMP2 expression in the C/EBPβ-depleted I4 cells 
(Supplemental Figure S1). These results further confirm the 
idea that S100A4 is a mediator of the effects of C/EBPβ in 
the invasion and motility capacities of glioblastoma cells.
In order to know whether S100A4 could also play a 
role in proliferation of GL261 and T98G cells, we performed 
“QIA127 Rapid Cell Proliferation Kit” assay both in control 
and C/EBPβ-depleted cells when S100A4 is overexpressed. 
As can be shown in Figure 7, we didn’t find any difference 
in growth and viability between control and S100A4-
overexpressing cells. These results are in agreement with 
data from Takenaga et al [35] showing that S100A4 is not 
involved in the growth of C6 glioblastoma cells.
Effect of C/EBPβ depletion on glioblastoma 
stem cells
The cancer stem cell (CSC) hypothesis suggests that 
tumors are organized in a hierarchy with a subpopulation 
of cells with stem cells properties, responsible for tumor 
maintenance and progression. Studies from our laboratory 
indicate that C/EBPβ is implicated in neural stem cells 
proliferation and differentiation in normal adult mouse 
brain [8]. In view of these data and based on our previous 
results showing that C/EBPβ plays an important role in 
the progression of tumorigenicity of glioblastoma cells, 
we finally analyzed whether C/EBPβ interference could 
also exert an antiproliferative effect on glioblastoma 
stem cells by analyzing its effect in glioblastoma-derived 
neurospheres (GNSF) and also if S100A4 levels were 
down-regulated in C/EBPβ-depleted GNSFs.
To ensure that we were working with an enriched 
population in GNSF, we first analyzed by western blot the 
protein levels of Musashi-1 and Oct3/4, which are well-
known stem cells markers [36]. As expected, adherent C1 
and I4 cells did not have Mushashi-1 and Oct3/4 proteins, 
while GNSF populations of PC1 and PI4 presented 
detectable levels of these markers (Figure 8A). Also, we 
observed a decrease in the levels of Musashi-1 in PI4 cells, 
compared to PC1, suggesting that C/EBPβ can alter the 
population of stem cells present in these cultures.
Next, we analyzed the basal level of expression 
of C/EBPβ in murine GNSF populations obtained from 
control C1 line and C/EBPβ-depleted I4 cells (PC1 and 
PI4 pools, respectively). Our results show that as happened 
in adherent C1 and I4 cells, PI4 cultures presented a 
significant (80%) decrease in the expression levels of 
C/EBPβ (Figure 8B). This reduction in C/EBPβ levels 
was accompanied by a large reduction in S100A4 
levels, indicating that C/EBPβ is also able to regulate 
S100A4 expression in the subpopulation of glioblastoma 
stem cells.
We then studied whether C/EBPβ interference 
could affect the formation capacity and self-renewal of 
GNSF population in GL261 glioblastoma cells. Figure 
8C shows that C/EBPβ depletion decreases the formation 
of primary glioblastoma neurospheres. We observed a 
significant decrease, at 7 days of culture, in the number 
of PI4 glioblastoma neurospheres, as compared to control 
PC1 cultures. To analyze more deeply the effect of C/
EBPβ depletion on the ability of GBM cells to generate 
new spheres, actively growing 7 day-old GL261-derived 
primary GNSF cultures were dissociated, and equal 
numbers of viable cells were replated in fresh neurosphere 
medium to generate new GNSF (secondary glioblastoma-
derived neurospheres). After 14 days, we observed that the 
formation of secondary GNSF were significantly less in 
the C/EBPβ-depleted cells (PI4), compared with control, 
PC1 (63 ± 21.5 and 235 ± 46.5 per plate, respectively) 
(Figure 8D). Furthermore, to test for the effect of C/
EBPβ interference on the self-renewal of the glioblastoma 
neurospheres, we dissociated established 7 days-old 
primary GNSF cultures and plated them at very low density 
during 7 and 14 days. As shown in Figure 8E, 8C/EBPβ-
depleted cultures (PI4) presented less number of secondary 
GNSF, 7 and 14 days after plating, compared with control 
population, PC1 (14 days after plating values were 8 ± 2.5 
and 19 ± 3.0 per plate, respectively), indicating that these 
cultures contain less self-renewing stem cells.
Lastly, we evaluated whether the S100A4 promoter 
was also regulated in the GNSF cultures by C/EBPβ. 
Consistent with the transfection data using GL261 
adherent cells, we found a substantial increase in the 
basal activity of the pS100A4/1248 construct containing 
S100A4 promoter in those GNSF co-transfected with the 
pcDNA3/C/EBPβ overexpression construct (Figure 8F). 
Also, deletion of C/EBPβ and AP1 binding sites, as 
well as site-specific mutations in both sites, significantly 
attenuated C/EBPβ-induced activity of this promoter.
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Figure 4: Effect of C/EBPβ and S100A4 on GL261 cells motility. C1, I4 and I5 cells transfected with the S100A4 expression 
vector pIRES2-DsRed-Express or the corresponding control vector were grown until reach confluence. A linear scratch was performed 
with a plastic pipette tip. Images were taken with a phase contrast microscope at different times after wounding. (A) Representative phase-
contrast images and (B) quantifications of the in vitro wound-healing assay are shown. Bar scale 100 μm. ***p < 0.001; *p < 0.05.
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DISCUSION
Glioblastomas (GBM) are the most common 
brain tumor in adults. Currently this devastating 
disease is practically incurable and the patients show 
a mean survival time of approximately one year after 
diagnosis [37], despite the use of surgery, radiotherapy 
and chemotherapy [38]. Studies of gene expression in 
glioblastomas have allowed analyzing the transcriptional 
activity present in these tumors, allowing the 
classification and prediction of response to particular 
treatments [39–41].
In a previous work [18] we have demonstrated that 
C/EBPβ is crucial to regulate glioblastoma cell growth 
and transformation. These findings are in accordance with 
the results of Carro et al [42] showing that the expression 
of C/EBPβ is linked to the mesenchymal state of primary 
glioblastoma and provides an excellent prognostic 
biomarker for tumor aggressiveness. These authors showed 
that C/EBPβ, together with STAT3, act synergistically 
to initiate and regulate mesenchymal transformation. 
Overexpression of these transcription factors reprograms 
neural stem cells throughout the aberrant mesenchymal 
lineage and enhances tumor aggressiveness.
Figure 5: Effect of C/EBPβ and S100A4 on T98G cells invasion capacity. (A) Representative western blot of C/EBPβ and 
S100A4 in control (TC) and C/EBPβ interfered (TI) T98G cells. (B) Representative western blot showing S100A4 levels in all the cell lines 
used for the invasion analysis. (C) The invasion capacity of TC and TI cells transfected with the S100A4 expressing vector pIRES2-DsRed-
Express or the corresponding control vector was determined on transwell chambers coated with Collagen Type IV as described in Materials 
and Methods. (C) Representative images and (D) quantifications are presented. Values are the means ± S.D. of three different experiments. 
Scale bar 50 μm. ***p < 0.001; *p < 0.05.
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Also we showed that C/EBPβ regulates several 
genes involved in DNA repair, invasion and metastasis, 
suggesting that these genes could be important downstream 
effectors of C/EBPβ-mediated oncogenic properties 
[18]. One of these genes is S100A4, which is known to 
promote invasion and metastasis in different tumor cells 
[31]. In this regard, Yonemura et al. demonstrated that 
55% of gastric cancer patients exhibited elevated S100A4 
levels, which were found to be positively associated with 
high incidence of metastasis. This study also showed 
that patients with low expression of S100A4 have lower 
number of metastatic lesions [43]. With respect to glial 
tumors, it has been shown that S100A4 is expressed 
differentially in astrocytic tumors being its levels higher 
on those tumors with a higher degree of malignancy [44].
In the present study, we show that the transcription 
factor C/EBPβ directly regulates the expression of 
metastatic protein S100A4 in a mouse glioblastoma cell 
Figure 6: Effect of C/EBPβ and S100A4 on T98G cells motility. TC and TI cells transfected with the S100A4 expressing vector 
pIRES2-DsRed-Express or the corresponding control vector were grown until reach confluence. A linear scratch was performed with a 
plastic pipette tip. Images were taken with a phase contrast microscope at different times after wounding. (A) Representative images and 
(B) quantifications of the in vitro wound-healing assay are shown. Bar scale 100 μm. ***p < 0.001; **p < 0.01.
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line and that this regulation may underlie the effects 
of C/EBPβ in the invasiveness of glioblastoma cells. 
The expression of S100A4 is very low in both mouse 
GL261 and human T98G glioblastoma cells depleted 
of C/EBPβ, which is associated with a decreased in 
migration and invasiveness capacity of these cells. 
The migratory and invasiveness activities of these cells 
was significantly increased in C/EBPβ-depleted cells 
overexpressing S100A4, suggesting that this protein could 
be mediating the effects of C/EBPβ on these processes. 
These results, suggest that S100A4 is a mediator of C/
EBPβ effects specifically on cell migration and invasion 
capacity of glioblastoma cells and are in accordance with 
previous reports showing a direct relationship between 
S100A4 expression and cell migration in astrocytic 
tumor cells, such as C6 [35], neuroblastoma cells [45] 
and medulloblastoma cells [46]. Our data showing that 
S100A4 does not enhance proliferation either control or C/
EBPβ-depleted cells, suggest that the differences observed 
were indeed due to differences in cell migration and not to 
an effect of S100A4 in cell growth.
S100A4 belongs to a large family of calcium 
binding proteins, many of which are involved in 
tumorigenic processes [47, 48] including regulation of 
cell motility, invasion, and migration. In this work we also 
show that the levels of three of these proteins, S100A6, 
S100A8, and S100A10, are also regulated by C/EBPβ. 
This lends support to the view that this transcription factor 
is an important regulator of different steps of tumorigenic 
processes in part due to its regulation of different members 
of the S100 family. Furthermore, these results are in 
agreement with previous data showing a modulation of 
the levels of these proteins in different cancer cells [49].
Sequence analysis revealed that the S100A4 
promoter contains 2 putative C/EBPβ-binding sequences, 
which could mediate the transcriptional regulation 
of this gene by C/EBPβ (one C/EBPβ and one AP1 
consensus binding sites). Our data provide evidence that 
C/EBPβ directly interacts with both sites at the S100A4 
promoter regulating its expression. Both, the deletion of 
a large fragment (almost 1 Kb) of the upstream region 
containing C/EBPβ and AP1 binding sites, and mutations 
of the sequences of these sites, clearly reduced C/EBPβ 
regulation of S100A4 promoter expression. Similar results 
were obtained when regulation of S100A4 transcriptional 
activity was evaluated in the GCSC subpopulation. These 
data, together with the ChIP analysis indicate that C/EBPβ 
directly regulates S100A4 gene expression. It is interesting 
to note that it has been reported that after a neural damage, 
the expression of C/EBPβ [11] and S100A4 [50] is 
induced, both in vitro and in vivo.
There is mounting evidence that neural stem cells 
can be transformed into cancer stem cells and give rise 
to malignant gliomas by escaping the mechanisms that 
control proliferation and programmed differentiation 
[51] [52, 53]. In fact, glioblastomas where among the 
first solid tumors where a cancer stem cell subpopulation 
was identified [54]. Here, we have also analyzed whether 
S100A4 was also present in the GCSC subpopulation 
and if its expression was also regulated by C/EBPβ, as it 
happened in adherent glioblastoma cells. Also we studied 
if C/EBPβ depletion had any effect upon this glioblastoma 
stem cells subpopulation. Our findings demonstrate 
that the S100A4 protein is highly expressed in GCSCs 
and that its expression is completely abolished in those 
GCSCs depleted of C/EBPβ. Moreover, by using transient 
tranfection experiments with the S100A4 promoter, we 
here show that S100A4 is also directly regulated by C/
EBPβ in GCSCs. In this regard, it is interesting to note that 
the abundance of S100A4 has been positively correlated 
Figure 7: Effects of C/EBPβ and S100A4 expression on cell proliferation. The proliferation of mouse (C1, I4 and I5) and 
human (TC and TI) cells transfected with the S100A4 expressing vector pIRES2-DsRed-Express or the corresponding control vector was 
determined using “QIA127 Rapid Cell Proliferation Kit”, as indicated in Methods. Cells were seeded into individual wells of a 96-well 
plate and cultivated for 24 h after which WST-1 was added to the culture medium. The cleavage of the WST-1 was quantified by absorbance 
measurement at 450 nm. Values are the means ± S.D. of three different experiments in triplicate.
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Figure 8: Effect of C/EBPβ depletion on GL261 stem cells. (A) Representative Western blot showing expression of Musashi-1 
and Oct3/4 in adherent C1 and I4 cell lines and neurospheres cultures (GNSF) from PC1 and PI4 7 days after plating. (B) Representative 
Western blot showing expression of C/EBPβ and S100A4 in neurospheres cultures derived from C1 and I4 cells (PC1 and PI4, respectively). 
(C) Representative images of primary GNSF from PC1 and PI4 cells. (D) Primary GNSF were dissociated and grown during 14 days to 
analyze secondary GNSF formation. Quantification of secondary GNSF was performed counting 12 randomly selected fields in 3 different 
wells. Within each assay the experiments were performed in triplicates. Values represent the means ± SD. **p < 0.01 (E) Representative 
microphotographs showing self-renewal capacity of neurosphere cultures from PC1 and PI4 cells 7 and 14 days after plating. Quantification 
of new GNSF after 14 days growing was performed counting 12 randomly selected fields in 3 different wells. Scale bar 250 μm. **p < 0.01 
(F) Transient transfection experiments in GNSF. The entire promoter fragment (pS100A4/1248), a 5’-deletion construct (pS100A4/298), 
and two constructs containing the mutated C/EBPβ (pS100A4/Mut-C/EBPβ) and the mutated C/EBPβ and AP1 binding sites (pS100A4//
Mut- C/EBPβ-AP1) were created as indicated in Methods. Data are expressed relative to the basal values and represent the mean ± SD 
luciferase activity determined in triplicate in at least three independent experiments. ***p < 0.001.
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to the self-renewal capability and stemness of different 
cancer stem cells by other authors [55] [28, 56]. Indeed, 
Harris et al [28] suggest that S100A4 could be a candidate 
marker for these cells. The results here obtained confirm 
the data of these authors and also suggest that C/EBPβ 
could also be regulating the invasive capacity of CSC 
through the regulation of the S100A4 gene.
The data presented here show that C/EBPβ 
interference has a growth inhibitory effect not only upon 
the bulk of glioblastoma cells, as previously shown by 
our group [18] but also on the glioblastoma stem cell 
population. The decreased on C/EBPβ expression results 
in a reduction of neurospheres formation and expansion in 
culture, as well as their capacity of self-renewal. These data 
suggest that C/EBPβ is able to both inhibit the growth of the 
bulk of the tumor, characterized by actively cycling cells, 
but also to hinder the growth and motility of glioblastoma 
stem cells characterized by a low rate of division and high 
metastatic capacity. This effect of C/EBPβ is probably 
independent of S100A4 regulation as shown by the lack of 
effect of S100A4 on cell growth. This effect of C/EBPβ is 
probably independent of S100A4 regulation as shown by 
the lack of effect of S100A4 on cell growth.
Overall, our findings suggest that targeting C/EBPβ 
in glioblastoma cells could have a therapeutic benefit by 
directly inhibiting the S100A4 gene, which is known to be 
involved in tumor invasiveness. Our results also point to a 
role of C/EBPβ on the maintenance of stem cells present 
in glioblastomas.
METHODS
Cell culture and C/EBPβ-shRNA stable 
transfection
GL261 murine glioblastoma cells were obtained 
from the NCI-Frederick Cancer Research Tumor 
Repository (Frederick, MD) and propagated in RPMI 
medium with 10% fetal bovine serum as described [57]. 
To knockdown C/EBPβ expression, siRNA sequences 
against mouse C/EBPβ and a non-targeting siRNA 
control were obtained from Dharmacon (Thermo 
Scientific, Waltham, MA). The interfering selected 
sequence was 5′-GAG CGA CGA GTA CAA GAT GTT 
CAA GAG ACA TCT TGT ACT CGT CGC TCT T-3′. 
The oligonucleotides were annealed and the double-
stranded oligonucleotides were cloned into pSilencer 
4.1vector (Ambion, Austin, TX), in which siRNAs were 
expressed under the control of the CMV promoter. The 
construct was verified by DNA sequencing. The plasmids 
(control or C/EBPβ-shRNA) were transfected into 
GL261 glioblastoma cells by using Lipofectamine 2000 
(Invitrogen, CA) and pools were selected using 400 μg/
ml of G418 and maintained in this selection medium. 
Pools C1 (expressing a non-targeting siRNA control) 
and I4 (expressing a siRNA against C/EBPβ) [18] were 
used throughout the study. T98G human glioblastoma 
cells were obtained from the ATCC (American Type 
Culture Collection) and propagated in EMEM medium 
with 10% fetal bovine serum. C/EBPβ expression was 
silenced in T98G cells using the FUGW lentiviral vector 
(obtained from Dr. Quintanilla-Martinez, Department 
of Dermatology, Eberhard Karls University, Tübingen-
Germany). The interfering selected sequence was: 5′- 
GAAGACCGTGGACAAGCAC -3′ (pool TI). A non-
targeting sequence (5′- GCCGCTTTGTAGGATAGAG -3′, 
pool TC) was used as control. In addition to the interfering 
and control sequences, the lentiviral vectors also express 
the GFP protein. For lentiviral production, 293T cells 
were transiently transfected with the appropriate lentiviral 
expression vector and the vectors pMD2-G, pMDLg/
pRRE, and pRSV-Rev, which encode lentiviral proteins. 
The medium containing the lentiviruses was recovered, 
filtered through a 0.45-μm filter and used to infect T98G 
cells. The infection was repeated 8 h and 24 h later. Pools 
TC (expressing a non targeting shRNA) and TI (expressing 
a shRNA against C/EBPβ) were used in this study.
Quantitative real-time PCR
Total RNA was extracted from C1, I4 and I5 
pools by using TRIzol (Invitrogen, Carlsbad, CA) as 
recommended by the manufacturer. Complementary DNA 
was generated using Superscript III kit (Invitrogen). PCR 
was performed on ABI Prism 7700 Sequence Detector 
(Applied Biosystems) using TaqMan probes (Applied 
Biosystems) specific to S100A4 and β-actin, following 
the manufacturer’s protocol. S100A6, S100A8, and 
S100A10 and MMP2 mRNA levels were analyzed by 
qRT-PCR using Fast SYBR Green Master Mix (Applied 
Biosystem) and 300 nM concentrations of specific primers 
(listed in Supplemental Table SI). In all samples, each 
specific sequence was measured at least twice in triplicate. 
Data were analyzed using the 2-∆∆Ct method [58] and the 
housekeeping β-actin for normalization.
Immunoblot analysis
Cultured cells were harvested and lysed in ice-cold 
RIPA buffer and equal quantities of total protein were 
separated by 10% SDS-PAGE. After electrophoresis, 
proteins were transferred to nitrocellulose membranes 
(Protran, Whatman, Dassel, Germany) and blots were 
probed with the indicated primary antibodies, as 
previously described (Cortes-Canteli et al., 2004). The 
antibodies used were the following: rabbit polyclonal 
anti-C/EBPβ, rabbit polyclonal anti-Oct3/4 (Santa Cruz 
Biotechnology, CA), rabbit polyclonal anti-S100A4 
(Abcam), rabbit polyclonal anti-Musashi-1 (Abcam) and 
mouse monoclonal anti-α-tubulin (Sigma). Secondary 
peroxidase-conjugated donkey anti-rabbit and rabbit 
anti-mouse antibodies were from Amersham Biosciences 
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(GE Healthcare, Buckinghamshire, England) and Jackson 
Immunoresearch, respectively. The Western blots shown 
in Figures 1, 3, 5 and 8 are representative of at least three 
independent experiments.
Chromatin immunoprecipitation
ChIP analysis was performed essentially as 
described [59]. For immunoprecipitation, the following 
antibodies were used: 5 μg of rabbit polyclonal anti-C/
EBPβ and 2 μg of normal rabbit IgG (Santa Cruz 
Biotechnology, CA). The precipitated DNA was analyzed 
by PCR using the following primers:
C/EBPβ, sense: 5′-TCCTGACTCCCCCTTTTAC 
C-3′; antisense: 5′-GGAGGCCAT GATGGAGTTAG-3′. 
AP-1, sense: 5′-CCCCGAATTTGTACCCTATC-3′; 
antisense: 5′-AGCATTCGGGGTTGAATGT-3′. β-actin, 
sense: 5′-TTGTAACCAACTGGG ACGACATGG-3′; 
antisense 5′-GATCTTGATCTTCATGGTGCTAGG-3′.
Generation of mouse S100A4 promoter 
constructs
Mouse S100A4 promoter was PCR-amplified 
from mouse genomic DNA using the high fidelity 
PCR-Extender System DNA polymerase (5-Prime, 
Gaithersburg, MD). PCR reactions were performed 
according to the manufacturer’s recommendations. 
The amplified products, a long promoter fragment 
from positions –1248 to +267, (pS100A4/1248) and a 
5’-deletion construct of the pS100A4/1248 promoter, 
from positions –298 to +267, (pS100A4/298) were 
cloned in the promoterless luciferase reporter vector 
pGL4.10. The primers used are listed in Supplementary 
Table SII. Mutant constructs of mouse S100A4 
promoter were generated with the Quick Change Site-
Directed Mutagenesis Kit (Stratagene, La Jolla, CA), 
using the S100A4 promoter cloned in the reporter 
plasmid pGL4.10 as a template. Specific mutations 
were incorporated by polymerase chain reaction 
using Pfu Turbo DNA Polymerase and subsequent 
digestion with DpnI, to eliminate the methylated 
parental band. The sequences were confirmed by 
sequencing. The mutants generated were pS100A4/
Mut-C/EBPβ, where the C/EBPβ binding site at –606/ 
–591 was mutated (from TGTCATTCCTCAATATC to 
TGAGCGGGGGGCCGCAC) and pS100A4/Mut-C/
EBPβ-AP1 where both, the C/EBPβ (as previously 
indicated) and the AP1 binding sites at 680/−670 (from 
CCTGACTCCCC to GGGCCGGGGGG) are mutated.
Transient transfections
For transient transfection experiments, semi-
confluent GL261 cells were transfected with lipofectamine 
2000 (Invitrogen) using different constructs: pS100A4/1248 
(complete promoter), pS100A4/Mut-C/EBPβ, pS100A4/
Mut-C/EBPβ-AP1 or pS100A4/298 (a deletion construct 
lacking the consensus C/EBPβ- and AP1-binding sites: 
–298/+267) in the presence or absence of pcDNA3-C/
EBPβ (C/EBPβ overexpression plasmid). Forty-eight hours 
after transfection, cells were harvested for determination 
of luciferase activity by using a reporter assay system 
(Promega, Madison, WI). β-galactosidase was used 
to determine transfection efficiency. Each transient 
transfection experiment was repeated at least three times 
in triplicate.
Cell invasion, migration and wound healing 
assay
The plasmid pIRES2-DsRed-Express containing 
S100A4 cDNA obtained from Dr. Stephan Lorenz (Faculty 
of Medicine, University of Leipzig, Germany) was 
transfected into mouse GL261 (C1, I4 and I5) and human 
T98G (TC and TI) cells to overexpress S100A4 protein.
Tumor cell invasion assays were performed using 
Transwells chambers (Costar) with 12-μm (mouse cells) 
or 8-μm pores (human cells) coated with a layer of 
Collagen type IV (50 μg/ml) free of growth factors (BD 
Biosciences). Medium with 20% fetal bovine serum was 
added to the lower chambers of the Transwells. Mouse 
(C1, I4 and I5) and human cells (TC and TI) were seeded 
(50,000 and 150,000 cells respectively) on top of the 
Transwell in triplicate in medium without serum and 
incubated at 37º for 48 h. At the end of the experiments, 
the bottom filters were fixed and stained with DAPI in 
the case of mouse cells. For human cells, GFP was used 
for cell quantification. Cells in the top chambers were 
removed by wiping with cotton swabs, and the stained 
cells that had migrated through the Collagen IV were 
counted under a microscope. Ten randomly selected 
20x microscopic fields were counted using the ImageJ 
program.
Wound healing assay was used to detect the 
alteration of cell motility. The different cells lines were 
seeded onto 60-mm plates and, after overnight incubation, 
an artificial wound was created using a P200 pipette tip to 
scratch on the confluent cell monolayer. Photomicrograph 
was taken immediately (time 0 h), so that the migrating 
cells and closing of scratch wound could be observed. 
Microphotographs were also taken at 24, 48 and 72 h 
post-wounding. Within each assay the experiments were 
performed in triplicate.
Transfection efficiency using lipofectamine 2000 
(as  measured by the percentage of red-fluorescent cells) 
was ~60%.
Cell proliferation assay
The effects of C/EBPβ and S100A4 expression on 
cell proliferation were determined using the “QIA127 
Rapid Cell Proliferation Kit” (Calbiochem), according 
to the manufacturer’s protocol. Mouse and human cells 
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transfected or not with the plasmid pIRES2-DsRed-
Express overexpressing S100A4 were seeded in triplicate 
onto 96-well plates at a density of 10,000 cells/well for 
mouse cells and 20,000 cells/well for human cells. After 24 
h of growth, cells were treated with 10 μl of the tetrazolium 
salt WST-1 labeling mixture, to each well. Cells were 
incubated for 2 h at 37ºC. The cleavage of the WST-1 was 
quantified by absorbance measurement at 450 nm.
Glioblastoma neurosphere (GNSF) formation
For GNSF formation C1 and I4 cells were plated and 
grown in regular medium (RPMI, 10% FBS, glutamine, 
gentamicine and fungizone). Two days after plating, 
supernatant was collected, centrifuged and cells were 
replated in a defined serum-free tumor sphere Ham’s F-12/ 
Dulbecco’s modified Eagle’s medium (1:1) supplemented 
with B27 (Invitrogen, Carlsbad, CA), 20 ng/ml epidermal 
growth factor (EGF, Peprotech, EC) and 20 ng/ml fibroblast 
growth factor (FGF, Peprotech, EC). After 1 week in culture 
some primary GNSF control (PC1) and C/EBPβ-depleted 
(PI4) were formed. These primary GNSF were then 
dissociated, and 50,000 cells/ml were replated in proliferative 
conditions and grown for another 14 days to score the 
number of secondary neurospheres generated. For self-
renewing experiments, primary glioblastoma neurospheres 
were dissociated and plated at a density of 2,000 cells/ml for 
another 7 or 14 days in proliferative medium. These assays 
were repeated at least three times in triplicate.
For reverse transfection experiments, cultured 
GNSF were used. A reverse transfection protocol was 
performed to deliver pS100A4/1248 (complete promoter), 
pS100A4/Mut-C/EBPβ, pS100A4/Mut-C/EBPβ-AP1 
or pS100A4/298 (a deletion construct lacking the 
consensus C/EBPβ- and AP1-binding sites: −298/+267) 
in the presence or absence of pcDNA3-C/EBPβ (C/
EBPβ overexpression plasmid) into GNSFs. Briefly, a 
transfection complex was prepared by diluting constructs 
(final plasmid concentration: 1 μg/well) in 100 μL OPTI-
MEM (Invitrogen), then adding 100 μL OPTI-MEM 
containing 1 μL Lipofectamine 2000 transfection reagent 
(Invitrogen). Neurospheres were disaggregated and 
2 × 104 cells seeded in a 24-well plate, and transfected 
with the above-mentioned complex. Forty-eight hours 
after transfection, cells were harvested for determination 
of luciferase activity by using a reporter assay system 
(Promega, Madison, WI). β-galactosidase was used to 
determine transfection efficiency. Each transfection 
experiment was repeated at least three times in triplicate.
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